Sugi Predict

Sugi Predict / Compounds / SCHEMBL8007984

SCHEMBL8007984

SCHEMBL8007984

CO/N=C(/C(=O)O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.48
▸ GAA P10253 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ CES1 P23141 5/20 0.42
▸ CES2 O00748 4/20 0.42
▸ TYMP P19971 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ F2 P00734 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ DAO P14920 1/20 0.41
▸ NAPRT Q6XQN6 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ CDK5 Q00535 2/20 0.40
▸ CDK5R1 Q15078 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3689392 1.00 TSHR (0.48) TSHRGAACYP2C19CES1CES2
SCHEMBL3958996 1.00 TSHR (0.48) TSHRGAACYP2C19CES1CES2
SCHEMBL2045476 0.87 TSHR (0.44) TSHRGAACYP2C19CES1CES2
SCHEMBL2045474 0.87 TSHR (0.44) TSHRGAACYP2C19CES1CES2
SCHEMBL9900446 0.86 CES2 (0.50) TSHRGAACYP2C19CES1CES2
SCHEMBL9900449 0.86 CES2 (0.50) TSHRGAACYP2C19CES1CES2
SCHEMBL3689389 0.86 TSHR (0.47) TSHRGAACYP2C19CES1CES2
SCHEMBL3689388 0.86 TSHR (0.47) TSHRGAACYP2C19CES1CES2
SCHEMBL7805644 0.86 CES1 (0.48) TSHRGAACYP2C19CES1CES2
SCHEMBL7651351 0.86 CES1 (0.48) TSHRGAACYP2C19CES1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1111536-C Preparation method of 13-ester derivatives of milbemycins and intermediates thereof SANKYO CO (JP) 2003-06-18 — — CN claimed
CN-1310719-A Process for producing 13-ester derivatives of milbemycins SANKYO CO (JP) 2001-08-29 — — CN claimed
US-20240241437-A1 SEMICONDUCTOR PHOTORESIST COMPOSITION AND METHOD OF FORMING PATTERNS USING THE COMPOSITION SAMSUNG SDI CO., LTD. (KR) 2024-07-18 — — US disclosed
US-20240241437-A1 SEMICONDUCTOR PHOTORESIST COMPOSITION AND METHOD OF FORMING PATTERNS USING THE COMPOSITION SAMSUNG SDI CO., LTD. (KR) 2024-07-18 — — US disclosed
US-10737280-B2 Method of using flotation collector containing azolethione structure CENTRAL SOUTH UNIVERSITY (CN) 2020-08-11 — — US disclosed
US-20190217310-A1 METHOD OF USING FLOTATION COLLECTOR CONTAINING AZOLETHIONE STRUCTURE CENTRAL SOUTH UNIVERSITY (CN) 2019-07-18 — — US disclosed
US-9925193-B2 Thioether derivatives as protein kinase inhibitors PROQINASE GMBH (DE) 2018-03-27 — — US disclosed
EP-2922857-B1 THIOETHER DERIVATIVES AS PROTEIN KINASE INHIBITORS PROQINASE GMBH (DE) 2018-01-03 — — EP disclosed
US-9388124-B2 Ingenol-3-acylates I LEO LABORATORIES LIMITED (IE) 2016-07-12 — — US disclosed
US-20150328219-A1 THIOETHER DERIVATIVES AS PROTEIN KINASE INHIBITORS PROQINASE GMBH (DE) 2015-11-19 — — US disclosed
EP-2922857-A1 THIOETHER DERIVATIVES AS PROTEIN KINASE INHIBITORS KTB Tumorforschungsgesellschaft mbH (DE) 2015-09-30 — — EP disclosed
CN-1310719-A Process for producing 13-ester derivatives of milbemycins SANKYO CO (JP) 2001-08-29 — — CN disclosed
JP-2000044571-A PRODUCTION OF 13-ESTER DERIVATIVES OF MILBEMYCIN COMPOUNDS SANKYO CO LTD 2000-02-15 — — JP disclosed
EP-0675133-B1 13-Substituted milbemycin derivatives, their preparation and use SANKYO CO (JP) 2000-01-12 — — EP disclosed
EP-0877730-A1 ARYL ACRYLICS FOR USE AS FUNGICIDE MONSANTO COMPANY (US) 1998-11-18 — — EP disclosed
WO-1997016413-A9 ARYL ACRYLICS FOR USE AS FUNGICIDE — 1997-08-14 — — WO disclosed
WO-1997016413-A1 ARYL ACRYLICS FOR USE AS FUNGICIDE MONSANTO COMPANY (US) 1997-05-09 — — WO disclosed
US-5614470-A AGRICULTURAL ANTHELMINTIC, ACARICIDE, INSECTICIDE SANKYO COMPANY, LIMITED (JP) 1997-03-25 — — US disclosed
EP-0675133-A1 13-Substituted milbemycin derivatives, their preparation and use SANKYO COMPANY LIMITED (JP) 1995-10-04 — — EP disclosed
US-4138555-A BACTERICIDES GLAXO LABORATORIES, LIMITED (GB) 1979-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240241437-A1 SEMICONDUCTOR PHOTORESIST COMPOSITION AND METHOD OF FORMING PATTERNS USING THE COMPOSITION BPNT1, NISCH, LCP1 TSHR 3952/4885GAA 4452/4885CYP2C19 1953/4885
US-20150328219-A1 THIOETHER DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K1, MAP3K6, MAP3K20 TSHR 631/4885GAA 3802/4885CYP2C19 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.